The recorded history of coccidioidomycosis began in 1892 with the report of the illness of Domingo Escurra by Alejandro Posadas followed by a description of the first North American cases by Rixford and Gilchrist. Originally considered a protozoan, William Ophüls determined that Coccidioides was a fungus and that the lungs were the apparent initial site of infection. During the 1930s, both Gifford and Dickson determined that a self-limited illness, Valley Fever, was caused by the same fungus that caused the often fatal coccidioidal granuloma. Charles Smith, over a period of approximately 2 decades, comprehensively described the clinical and geographic epidemiology of coccidioidomycosis in California. Demosthenes Pappagianis continued this work after Smith's death. In 1957, one year before Marshall Fiese published his masterful monograph on coccidioidomycosis, the use of the first effective agent for the therapy of coccidioidomycosis, amphotericin B, was reported. This was followed by descriptions of its appropriate clinical use by William Winn and by Hans Einstein, among others. The development of the much less toxic azole antifungal agents greatly simplified therapy in many cases, but much of the management of patients with coccidioidomycosis still relies more on art than science. The search for the "Holy Grail" -a vaccine capable of preventing this disease-continues.
patient, converted my hunch into a near-certainty and histopathological examination of two small pieces taken from the most exuberant and striking lesions subsequently removed all doubt in my mind." "Last year, in a review and organization of the anatomic specimens in the museum of the Telémaco Susini Institute of Pathologic Anatomy and Physiology of the Faculty of Medical Sciences in Buenos Aires, Dr. R. Sammartino found a left foot and hand in a jar labeled 'tuberous leprosy' with macroscopic lesions matching those described by Posadas in his patient. Histologic study of the lesions allowed me to determine they were coccidioides granulomas and to identify the specimens as belonging-with high probability-to Posadas' patient."
Posadas' patient was, of course, Domingo Escurra. In 1889, Escurra, a 33-year-old cavalryman in the pampas of the Chaco Frontier in northern Argentina, noted what he believed to be a spider bite on his cheek. 2 This lesion worsened and additional ones appeared despite his application of tobacco and incisions with a penknife. Upon presentation to a military hospital, a diagnosis of lupus vulgaris was made, but, due to a lack of improvement despite local treatment with nitric acid, he was transferred to Rawson Hospital in San Juan, Argentina, where the diagnosis was changed to mycosis fungoides. Failing to respond to mercury and potassium iodide treatment, he was finally transferred to the University Hospital Clinics in Buenos Aires where he came under the care of an intern, Alejandro Posadas. Posadas ( Fig. 2) , 3 working under the supervision of Dr.
Robert Wernicke, microscopically examined biopsies of Escurra's lesions, which by now had appeared on his extremities and trunk 3, 4 (Fig. 3 ). 1 They observed multinucleated giant cells together with "psorospermiae" (i.e., protozoa) consisting of variably sized spherical sporangia, with granular contents within doubly refractile cell envelopes. 4 Having accepted the diagnosis of mycosis fungoides that had been made by Dr. M. Bengolea at the Rawson Hospital, Posadas believed he had discovered its etiology. Escurra's disease was progressive and ultimately fatalhe died in 1898, 6 years after Posadas published his landmark (Fig. 7) had a rapid downhill course to death, Silverra, whose illness had begun 5 years before his 1893 hospitalization, had a more slowly progressive one that, nevertheless, had the same fatal outcome (Fig. 8 ).
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Rixford and Gilchrist recognized that the organisms they were examining at appeared to be the same as those described by Posadas, and they agreed with him that they were protozoan. They placed the organism among the Sporozoa, and chose Coccidioides as the genus name because of the "coccidia-like" appearance. They named Silverra's organism Coccidioides immitis while Pereira's was called Coccidioides pyogenes, because of differences in their associated tissue inflammatory responses and clinical courses. Their strong belief that the organism was a protozoan is undoubtedly what led them to disregard the mould they repeatedly found growing on inoculated culture plates as contaminants. It was left to William Ophüls ( Fig. 9) , 12 15, 16 In subsequent publications, Ophüls described additional work, including a description of the organism's various morphologies and life cycle, its airborne route of transmission, and the fulfillment of Koch's postulates (Fig. 10) . 17 He also proposed a name for the disease caused by this pathogenic mould: "coccidioidal granuloma." Ophüls, who went on to become the second Dean of the Stanford Medical School, speculated that soil constituted an important reservoir for Coccidioides and this was confirmed in 1931 when the organism was recovered from soil under a bunkhouse in Delano, California, in which four infected farm laborers had slept. 18 This, of course, was consistent with Ophüls' suggestion that infection occurred by the airborne route. The first demonstration of the ability to recover the fungus from air samples was not, however, reported until decades later. 18a And if the soil is the reservoir for airborne transmission of the fungus, then animals that sniff soil should be frequently affected. And who sniffs soil more often than dogs? The first description of coccidioidomycosis in a dog (in Arizona), was not, however, published until 1940. 19 Subsequent evidence indicates that the recognition of coccidioidal infections in dogs has sentinel value in defining areas of risk for human infection. Other animals also, of course, become infected. Coccidioides infection may often be found in pen-fed or confined cattle at the time of slaughter in Arizona but, in contrast to, for example, dogs and humans, it does not appear to be associated with progressive disease. 19a The annals of the San Diego Zoo indicate that their first recorded animal death due to coccidioidomycosis was that of a tropical American monkey in 1936. 20 Six years later, Mbongo, one of the Zoo's gorillas, died of coccidioidomycosis, 11 years after its arrival. 20 It has more recently been recognized that, despite its soil reservoir, Coccidioides is surprisingly the most common cause of systemic mycotic infection among sea mammals along the California coast. These include southern sea otters and California sea lions found stranded along the state's central coast. 21 Besides coccidioidal granuloma, there was another clinical illness plaguing residents of the San Joaquin Valley of California that was more common but whose etiology was unknown. This much more benign and common malady, that was called, among other things, San Joaquin Valley fever, was often accompanied by eosinophilia and, in many instances, erythema nodosum, in addition to respiratory symptoms. The presence of eosinophilia led to the hypothesis that this illness was caused by a parasitic infection. This motivated Myrnie Ada Gifford ( Fig. 11) , 22 who had received her MD from Stanford and MPH from Johns Hopkins and in 1934 had become the Chief Assistant Health Officer of Kern County, California (in the heart of the endemic area in the San Joaquin Valley), to spend a portion of her first 17 months on the job fruitlessly trying to identify ascariasis as the cause of the illness. Her approach shifted when Coccidioides was recovered by guinea pig inoculation from the sputum of a patient with respiratory symptoms and erythema nodosum-that is, San Joaquin Valley fever. 23 Gifford subsequently reported that she had presented this case, together with the fact that 3 of 15 patients with "coccidioides fungus infection" of the lungs had concomitant erythema nodosum, to Ernest Dickson in January 1936. 24 Dickson (Fig. 12) , 25 a Stanford Professor of Public Health and Preventive Medicine, was visiting Bakersfield to obtain assistance in further investigating his observation that the occurrence of coccidioidal granuloma was often preceded by pneumonia. Gifford followed up her presentation by asking Dickson "if he thought there might be a relationship between San Joaquin Valley fever and the disease due to the Coccidioides fungus", which was known to be the cause of coccidioidal granuloma. 24 She went on in her report to say that: "He was immediately interested, as he recalled that their one laboratory case, Dr. C., had developed an unexplained erythema nodosum. . . ". "Dr. C." was Harold Chope, a Stanford medical student working in Dickson's laboratory who had accidentally inhaled a "brownish cloud" of Coccidioides arthrospores (now arthroconidia) and became ill 9 days later. On October 8, 1929, 41 days after the laboratory accident, the San Francisco Examiner reported that this "Modern Hero" a "youthful research man, faces death in a local hospital because of a mysterious mould breathed in while making an important experiment." 25, 26 Chope ( Fig.   13 ) 27 (who was ironically sent to Arizona to recuperate) did not, in fact, die until 1976 at the age of 72 years after a remarkable career in Public Health. The recognition that Chope's lengthy illness, which included pneumonia and the development of patients with erythema nodosum/multiforme and found that all reacted to skin testing with coccidioidin, a preparation derived from an extract of the mycelial phase of the fungus. He also went on to confirm an earlier observation by Gifford that most infections were asymptomatic as well as to establish the incubation period and demonstrate that skin test reactivity was associated with a favorable outcome. He defined endemic areas by studying coccidioidin skin test reactivity rates.
Maddy subsequently defined such areas in Arizona and identified them as largely coextensive with the Lower Sonoran Life Zone ecological niche. 32 Hugenholtz, working at Williams Air Force Base in Arizona, identified relationships between local weather conditions, particularly rainfall, dust, and temperature and the incidence of coccidioidomycosis. 32a Smith's further investigations established the frequency of complicated (including disseminated) infection and its association with certain ethnic groups. He developed serological means of diagnosis with the serendipitously discovered tube precipitin test which detected anti-coccidioidal immunoglobulin M (IgM) antibody and the complement fixing antibody (CFA) test that detected immunoglobulin G (IgG) antibody to antigens of the fungus. Smith also defined the time course of the rise and fall of these antibody titers and demonstrated the key clinically useful correlation between the height of the CFA titer and the extent of infection and risk of dissemination. 33, 34 In 1956 (also the year The recent recognition of the high rate of coccidioidomycosis in prisoners in the California Central Valley 41 created both a medical and a political disturbance-but one that should have been anticipated from experiences during and after World War II. The stationing of military personnel in endemic areas of Arizona and California and the internment of Japanese at sites along the Gila River in Arizona at that time led to frequent infections among these coccidioidal naïve populations. 42 Also affected were German prisoners of war in Florence, Arizona, and in California. 42 Noteworthy were the reviews of the known geographic extent of coccidioidomycosis in Mexico by Gonzalez-Ochoa and in the Americas in general by Negroni. 43, 44 Epidemiologists and clinicians have been confronted with an increased incidence of coccidioidomycosis. 45 They have been further tested by the need to manage an increasing number of cases in immunocompromised patients, 46 including those with acquired immunodeficiency syndrome as well as in hematopoietic stem cell and solid organ transplant recipients. 47, 48 Other events include the recent renewed commercial availability of a reformulated spherule-derived skin test preparation (no skin test reagent had been available since 1999) 49 and of a coccidioidal antigen test. 50 Finally, Fisher and colleagues discovered that Rixford had, in a sense, been correct when he decided a century earlier that there was a second coccidioidal species to accompany Coccidioides immitis-it just was not "Coccidioides pyogenes." The distinction between species has nothing to do with the clinical picture or histopathological response, but rather to genetic polymorphisms. The newly designated species was named in recognition of the physician who first reported the disease -Coccidioides posadasii. 51 Work utilizing molecular biological and genetic methodologies continues to expand, allowing improved understanding of the life cycle, biology, and population structure of Coccidioides, as well as the immune response to the fungus. The knowledge that surviving infection due to Coccidioides generally provides life-long protection from clinically apparent illness due to subsequent exogenous infection makes coccidioidomycosis a potential target for vaccine development. Attempts to date, however, have proven unsuccessful, but possible new paths forward have been proposed and are under exploration. 52 
Part II. Treatment
When Domingo Escurra's head was discovered in 1948, the chemotherapy of coccidioidomycosis was no more advanced, although perhaps less brutal, than it was when he had first presented for medical care more than a half-century earlier. Escurra had unsuccessfully self-treated his lesions with topical applications of tobacco as well as incisions. 2 The treatment of Joas Furtado Silverra included topical and intralesional methyl violet, iodine, and bromine, all without result, aside from the infliction of pain and, probably, further disfigurement. 10, 11 In fact, his treatment with intralesional bromine was discontinued because "injections were attended with so much suffering, notwithstanding the previous use of cocaine, that the attempt to continue them was abandoned." On March 17, 1894, under chloroform anesthesia, "all the affected areas . . . were most thoroughly scraped with a sharp spoon. The raw surfaces were then vigorously scrubbed with a bristle brush and an abundance of bichlorite solution . . . was applied." In 1931, the California Department of Public Health summarized the status of the treatment of coccidioidomycosis: r "Some . . . have reported apparent benefit from" X-ray therapy for superficial lesions.
r Vaccines were used "with, at best, very doubtful benefit." r Iodides, thymol, volatile oils, salvarsan and other arsenicals "have not proved of any value."
r Intramuscular colloidal copper, intravenous antimony potassium tartrate gave "more encouraging" reports.
r Amputation was the only curative intervention-but obviously only applicable to disease localized to an extremity.
In 1942, Charles Smith was asked to provide recommendations for the treatment of John Fulton, the Sterling Professor and Chair of the Department of Physiology at Yale University who developed severe pulmonary and disseminated coccidioidomycosis (possibly acquired during a visit to Smith's Stanford laboratory). 54 He suggested the following:
r Artificial pneumothorax. r (Continuation of) sulfa administration. r Trial of coccidioidin as a therapeutic vaccine. r Thymol injections into an abdominal wall abscess.
Smith was, at a minimum, undoubtedly skeptical that following his own advice would produce favorable results for Fulton. In fact, Smith's image later appeared in a 1949 Saturday Evening Post article entitled "The Mystery of the Deadly Dust" and which contained the following caption: "Thus far, no drug or vaccine has proved effective in prevention or cure." r Nystatin is active in an animal model, but is toxic. r Cycloheximide is reported to be "of value," but its activity is "feeble."
r Prodigiosin is reported to be "lifesaving" in disseminated infection, but "seems not to be the answer." r Stilbamidines are associated with "isolated reports of apparent cures," but no series were reported.
r Ethyl vanillate is "perhaps the most generally useful drug at the present time . . . but not the final answer" but it "at least . . . demonstrates that disseminated coccidioidomycosis, which has heretofore mocked our best efforts, is not necessarily incurable." A year later, ethyl vanillate, a byproduct in the production of paper pulp, received a rousing endorsement from Dr. Robert Cohen who stated "I have used ethyl vanillate since 1951 and it has not let me down." 57 He went on to describe its preparation for therapeutic use: "for two years the Wisconsin Institute for Paper Chemistry sent me bulk quantities of ethyl vanilla, which I melted on my wife's kitchen stove and poured into thousands of gelatin capsules." Just a few years after his presentation to the Stanford Medical Alumni, Fiese, shaking off the final remnants of a widely shared therapeutic illusion (a common affliction of clinicians to this day), revised his earlier assessment, 58 "an honest appraisal of 60 years of various forms of treatment. . . " compelled him to make these astute observations (among a total of 5):
r "The course of acute, fulminating, disseminated coccidioidomycosis has never been altered by any form of therapy, past or present."
r "Dramatic improvement of chronic, disseminated lesions has coincided with treatment by several methods and with many drugs. It has also occurred with no treatment whatsoever."
Fiese went on to publish a remarkably comprehensive monograph in 1958 that proved to be a tour de force, summarizing all that was known about coccidioidomycosis at the time. 59 He unfortunately tragically died 2 years later when the passenger train in which he was traveling (the San Francisco Chief) collided with a fuel truck near Bakersfield, California.
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Littman and colleagues, also in 1958, 61 summed up the then current state of therapeutics-using the phrase "clinical trials" very loosely: "Unsuccessful therapeutic agents which have received clinical trials include heavy metals, ethyl vanillate, gentian violet, sodium caprylate, stilbamidine, 2-hydroxystilbamidine, methyltestosterone, diethylstilbestrol, isonicotinic acid hydrazide, para-aminosalicylic acid, nitrogen mustard, potassium iodide, sulfonamides, the antibiotics [sic], penicillin, streptomycin, oxy-tetracycline, chlortetracycline, prodigiosin, protoanemonin, fradicin, thiolutin, rimocidin, actidione and nystatin, roentgen therapy, culture filtrates and extracts of C. immitis and immune human serum." While Fiese's therapeutic nihilism was a rational assessment of the situation at the time, things were about to change for the better. In January 1953, Streptomyces nodosum had been recovered from culture M 475 obtained from the soil of the Orinoco River Valley in Venezuela and was subsequently found to secrete 2 molecules with antifungal activity that were given the names amphotericin A and B. The latter proved more suitable for further development by Squibb Laboratories, 62 which had previously developed Brown and Hazen's Nystatin. Amphotericin B was quickly demonstrated to be effective in the treatment of Coccidioides infection in a murine model, 63 and its first intravenous administration to humans was reported in 1957. 63, 64 Prior to this, however, it had been given by the oral route with, at least in one case, some apparent degree of efficacy. Fiese had initiated the administration of 800 mg of amphotericin B by mouth every 8 hours in a patient with chronic disfiguring coccidioidal granuloma of the face on February 24, 1956, with subsequent clinical improvement that he documented with serial photographs. 65 In his discussion, however, Fiese was extremely apologetic for reporting this single case, acknowledging the prior history of enthusiasm for what ultimately proved to be ineffective therapies of this disease. Therapeutic investigations by Hans Einstein (Fig. 16 ) and William Winn (Fig. 17) , each working separately in the San Joaquin Valley, quickly led to the determination of the basics of administration of amphotericin B and indications for its use in patients with coccidioidomycosis, which were comprehensively summarized by 1963. 66 Importantly, this included the necessity of intrathecal administration of the drug when used for the treatment of coccidioidal meningitis, although the subsequent development of azole antifungals has significantly reduced this need.
The toxicities of amphotericin B unfortunately often necessitated limitations to its use, making the development of antifungal azole drugs a welcome advance. The first of the azoles, miconazole, however, required intravenous administration and was toxic, leading to its abandonment for systemic use. The approval of ketoconazole, an orally bioavailable azole, in 1981 was an important initial step forward, but it was subsequently supplanted by fluconazole and, later, itraconazole as well. Among other things, these drugs often proved effective in the treatment of coccidioidal meningitis, reducing the necessity intrathecal amphotericin B administration. The newer triazoles (voriconazole, posaconazole, isavuconazonium) provide additional alternatives, but their precise roles remain largely undetermined. In addition, the development of lipid-associated amphotericin B products has improved the systemic tolerability of this polyene antifungal, which is believed to remain the most potent agent available in the treatment of coccidioidomycosis.
Despite these advances, it can be argued that the treatment of coccidioidomycosis remains more art than science and that, despite the work of the Mycoses Study Group and others, progress has proceeded at a glacial pace. Among all the recommendations in the 2000 Infectious Diseases Society of America guideline for the treatment of coccidioidomycosis, none were rated as A-I (good strength of evidence based on at least one randomized controlled trial). 67 The 2016 revision of these guidelines switched to the GRADE rating system, but the results were the same-of the 61 recommendations, 54 were judged as strong-but none were based on high-level evidence! 68 This knowledge deficit can only be resolved through organizations such as the Coccidioidomycosis Center for Excellence and the Mycoses Study Group fostering collaborative efforts of clinicians in designing and implementing multicenter clinical trials-and with funding agencies to provide the necessary resources to advance therapeutics and vaccine development.
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